Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
about
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisNonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementTreatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight LossReview of nonalcoholic fatty liver disease in women with polycystic ovary syndromeEffects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesA Practical Approach to Gastrointestinal Complications of DiabetesCardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective studyPre-and-post transplant considerations in patients with nonalcoholic fatty liver disease.Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.Is there an effective therapy available for non-alcoholic fatty liver disease?Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin.Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Current status of therapy in nonalcoholic Fatty liver disease.Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in Bio F1B Golden Syrian hamsters.The metabolic syndrome and nonalcoholic fatty liver disease in childrenMechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly.PURLs: statins for patients with nonalcoholic fatty liver?Effect of Vitamin E and Metformin on Fatty Liver Disease in Obese Children- Randomized Clinical TrialReduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver DiseaseNAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trialCurrent treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation.Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease.The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial.Metformin protects rat hepatocytes against bile acid-induced apoptosisEvidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.Recent advances in understanding and managing non-alcoholic fatty liver disease.
P2860
Q24198072-747AB124-8A57-428B-8A4E-BA426E207F87Q24649618-F9AA73B1-07A7-4CF2-836B-421299C622A8Q26775632-ADC681B6-B26F-4C29-BAE5-37428A67FC32Q26828765-9D4CB218-18D5-4EA7-89B8-AF8AEE1EC461Q27025423-3FCE9711-39D0-46DC-940C-DDA4EB247DC7Q28071949-7389D125-A7E9-4CAE-BFFB-970CCBC1E0C5Q28074308-F4048A8F-8279-4C48-A0CF-8C697FAD3A04Q33891750-EEEF8A9B-8BC2-4970-B002-978BD7ACF673Q33937311-B6D66D98-A4AE-482E-ACE2-CEA925983F77Q34076451-01079091-B594-4FC5-9988-870E18F7315FQ34113354-38D16435-DC2E-4481-BB3A-75C65074CD21Q34168532-E6110885-95D1-4BE0-BBF2-D8B9EA4CF2B4Q34408961-E9B05124-EFFD-40A1-A8EF-3C136169EBABQ34648009-2B87466A-E222-4E4D-9012-BC85F63A95ECQ34778237-9D704A31-337D-490F-88CD-85459FBB2078Q35209849-68A2F5A6-F90D-458E-A4C8-2B71947C8C49Q35247558-27D4BB54-3940-4058-B253-6F8930E94AD1Q35639142-56EBCC34-3571-41A0-9B9F-4DF44CBF1BBBQ35947534-94F0CF89-86D6-4BEC-B311-5C3601BB5DEAQ36654473-EE3DE907-DB94-41E4-9A77-8409D635B62FQ37149405-38DC8971-D1C2-495D-85A7-3ACB36C23322Q37515585-9C2C8B64-6A7B-4197-9188-6681848C4561Q38020492-EDDE0E2B-3FF4-4788-867E-C0957528D7CFQ38682089-E8B83202-D666-475C-B8A4-FFEA14D3FBA2Q39646058-967BBB29-A878-4DA8-8B1A-B413B4C74B5EQ41172779-AE3EB81F-DA5E-4B61-B46B-7390EA34C10DQ42551151-93F35876-05E7-4E68-990E-18435F7C342EQ44908879-5CCDDC0F-1F82-476A-ABC7-34D3F7FDC8E3Q55359842-572FEF31-E5B0-4252-BBDE-B3FF4BA737F6
P2860
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@ast
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@en
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@en-gb
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@nl
type
label
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@ast
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@en
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@en-gb
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@nl
prefLabel
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@ast
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@en
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@en-gb
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@nl
P2093
P2860
P3181
P1476
Drugs improving insulin resist ...... non-alcoholic steatohepatitis
@en
P2093
Cesare Alessandri
Flavio Lirussi
Francesco Angelico
Marco Burattin
Maria Del Ben
P2860
P3181
P356
10.1002/14651858.CD005166.PUB2
P577
2007-01-24T00:00:00Z